A phase III trial of ilodecakin [AM0010] in combination with an anti-PD-1 checkpoint inhibitor(pembrolizumab) in patients with solid tumours
Phase of Trial: Phase III
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Ilodecakin (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Registrational; Therapeutic Use
- 09 Oct 2017 According to an ARMO BioSciences media release, Joseph Leveque, M.D. will lead this trial.
- 26 Sep 2016 According to an ARMO Biosciences media release, the company anticipates to initiate this study by the end of the year 2016.
- 26 Sep 2016 Planned initiation date changed from 1 Jan 2016 to 1 Dec 2016, according to an ARMO Biosciences media release.